Aventis Pharmaceuticals Inc.

Aventis Pharmaceuticals Products Inc.

Gregory G Kubiak

Matthew R Powers

Adam W Sledeski

Benoit J Vanasse

James P Sherbine

Zofia J Chrzan

James J Mencel

Walter Rodriguez

Rick G Woodward

Robert C Liu

Vincent Windisch

David Toledo-Velasquez

Anthony J Gardetto

Narasimha M Vemuri

Patrick Leon

Michael K O'Brien

Luc Grondard

Ching T Tsuei

Tory H Powner

Diane C Salazar

Laurence Pailleres-Hubert

Benoit Viguier

Diane C Salazar, Deceased

STABLE NON-HYGROSCOPIC CRYSTALLINE FORM OF N-&lsqb;N-&lsqb;N-(4-(PIPERIDIN-4-YL)BUTANOYL)-N-ETHYLGLYCYL&rsqb;ASPARTYL&rsqb;-L-&bgr;-CYCLOHEXYL ALANINE AMIDE, INTERMEDIATES THEREOF, AND PREPARATION THEREOF AND OF ANTITHROMBOTIC AZACYCLOALKYLALKANOYL PEPTIDES AND PSEUDOPEPTIDES

This invention is directed to a process for preparing N6-substituted adenosine derivatives, to intermediates useful therefor and to methods of preparing these intermediates.

Process for preparing N6-substituted adenosine derivatives

The invention is directed to a non-hygroscopic stable crystalline form of the antithrombotic compound N-[N-[N-(4-piperdin-4-yl)butanoyl)-N-ethylglycyl]-(L)-aspartyl]-(L)-.beta. -cyclohexyl-alanine amide, to processes for preparing said stable crystalline form, to a pharmaceutical composition thereof, and intermediates thereof, and the invention is directed also to processes for preparing a compound of the formula ##STR1## wherein: A, B, Z, E.sup.1, E.sup.2, G, R, m, n, and p are as defined herein.

Stable non-hygroscopic crystalline form of

Growing community of inventors

Wilmington, DE, United States of America

Gregory G Kubiak